Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
Deesje DoppenbergJacob L van DamYoungmin HanBert A BonsingOlivier R C BuschSebastiaan FestenErwin van der HarstIgnace H de HinghMarjolein Y V HomsWooil KwonMirang LeeDaan J LipsVincent E De MeijerI Quintus MolenaarJoost J NuyttensGijs A PatijnStijn van RoesselGeorge P van der SchellingMustafa SukerEva VersteijneJudith De Vos-GeelenJohanna W WilminkCasper H J van EijckGeertjan van TienhovenJin-Young JangMarc G H BesselinkBas Groot Koerkampnull nullPublished in: The British journal of surgery (2023)
Baseline serum CA19-9 level defined as either high or low has prognostic value, but was not associated with the treatment effect of neoadjuvant CRT in patients with resectable and borderline resectable pancreatic cancers, in contrast with current guideline advice.